Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vintafolide - Endocyte

Drug Profile

Vintafolide - Endocyte

Alternative Names: EC-145; Folic acid desacetylvinblastine hydrazine conjugate; MK-8109; VYNFINIT

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte
  • Class Amino acids; Antineoplastics; Folic acids; Hydrazines; Pterins; Sulfhydryl compounds; Vinca alkaloids
  • Mechanism of Action Microtubule protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Ovarian cancer
  • No development reported Non-small cell lung cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 06 Aug 2019 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Monotherapy, Second-line therapy or greater) in Poland, Germany, France, Spain, Russia, Romania, Hungary, Czech Republic, United Kingdom, Bulgaria, USA (IV) (Endocyte website, August 2019)
  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 07 Sep 2015 Final efficacy and adverse events data from a phase II trial in Non Small Cell Lung Cancer released by Endocyte
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top